1. Home
  2. GXO vs BLTE Comparison

GXO vs BLTE Comparison

Compare GXO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GXO Logistics Inc.

GXO

GXO Logistics Inc.

HOLD

Current Price

$48.45

Market Cap

5.5B

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$145.48

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXO
BLTE
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.2B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
GXO
BLTE
Price
$48.45
$145.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
7
Target Price
$67.91
$198.00
AVG Volume (30 Days)
1.1M
220.9K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$13,178,000,000.00
N/A
Revenue This Year
$6.81
N/A
Revenue Next Year
$5.95
$492.11
P/E Ratio
$1,615.67
N/A
Revenue Growth
12.55
N/A
52 Week Low
$45.40
$56.68
52 Week High
$66.85
$200.00

Technical Indicators

Market Signals
Indicator
GXO
BLTE
Relative Strength Index (RSI) 45.73 51.32
Support Level $48.58 $132.50
Resistance Level $55.55 $168.44
Average True Range (ATR) 1.39 8.50
MACD 0.13 1.35
Stochastic Oscillator 24.16 73.31

Price Performance

Historical Comparison
GXO
BLTE

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: